Abstract:

Cardiovascular disease (CVD) is the most common cause of death in chronic kidney diseases (CKD). Moreover，antiplatelet drugs（AA） or anticoagulants are the cornerstones  treatment of cardiovascular disease. AA are widely used in patients affected by CKD. However, hemodialysis patients, having an increased risk of periprocedural ischemic and bleeding complications, are excluded from most RCTs on revascularization；while, current treatment strategies are based on retrospective analyses of RCTs and data from registries. This article summarizes the recent progress in research  on antiplatelet agents in hemodialysis patients based on the studies and guidelines in recent years.

Key words: antiplatelet drugs, chronic kidney diseases, hemodialysis, cardiovascular disease